{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:01:43Z","timestamp":1795028503240,"version":"4.10.2"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41582-022-00679-w","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T08:03:21Z","timestamp":1655798601000},"page":"515-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":304,"title":["Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8340-9992","authenticated-orcid":false,"given":"Craig","family":"Horbinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"679_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231\u20131251 (2021). A comprehensive summary of the new WHO classification of CNS tumours, with an emphasis on new tumour types.","journal-title":"Neuro Oncol."},{"key":"679_CR2","unstructured":"WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Central Nervous System Tumours, 5th edn (WHO, 2021). The new WHO classification of CNS tumours, the largest and most molecularly driven classification to date."},{"key":"679_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1750-3639.1993.tb00752.x","volume":"3","author":"P Kleihues","year":"1993","unstructured":"Kleihues, P., Burger, P. C. & Scheithauer, B. W. The new WHO classification of brain tumours. Brain Pathol. 3, 255\u2013268 (1993).","journal-title":"Brain Pathol."},{"key":"679_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis, D. N. et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803\u2013820 (2016).","journal-title":"Acta Neuropathol."},{"key":"679_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","volume":"139","author":"DJ Brat","year":"2020","unstructured":"Brat, D. J. et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 139, 603\u2013608 (2020).","journal-title":"Acta Neuropathol."},{"key":"679_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","volume":"136","author":"DJ Brat","year":"2018","unstructured":"Brat, D. J. et al. cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u201d. Acta Neuropathol. 136, 805\u2013810 (2018).","journal-title":"Acta Neuropathol."},{"key":"679_CR7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/bpa.12838","volume":"30","author":"DW Ellison","year":"2020","unstructured":"Ellison, D. W. et al. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 30, 863\u2013866 (2020).","journal-title":"Brain Pathol."},{"key":"679_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00401-019-01987-0","volume":"137","author":"DW Ellison","year":"2019","unstructured":"Ellison, D. W. et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol. 137, 683\u2013687 (2019).","journal-title":"Acta Neuropathol."},{"key":"679_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-016-1646-x","volume":"133","author":"DN Louis","year":"2017","unstructured":"Louis, D. N. et al. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathol. 133, 1\u20133 (2017).","journal-title":"Acta Neuropathol."},{"key":"679_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-018-1826-y","volume":"135","author":"DN Louis","year":"2018","unstructured":"Louis, D. N. et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma\/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 135, 639\u2013642 (2018).","journal-title":"Acta Neuropathol."},{"key":"679_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bpa.12832","volume":"30","author":"DN Louis","year":"2020","unstructured":"Louis, D. N. et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 30, 844\u2013856 (2020).","journal-title":"Brain Pathol."},{"key":"679_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00401-018-1808-0","volume":"135","author":"DN Louis","year":"2018","unstructured":"Louis, D. N. et al. cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol. 135, 481\u2013484 (2018).","journal-title":"Acta Neuropathol."},{"key":"679_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40478-015-0270-7","volume":"4","author":"BH Hinrichs","year":"2016","unstructured":"Hinrichs, B. H. et al. Farewell to GBM-O: genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. Acta Neuropathol. Commun. 4, 4 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"679_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00401-014-1326-7","volume":"128","author":"F Sahm","year":"2014","unstructured":"Sahm, F. et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 128, 551\u2013559 (2014).","journal-title":"Acta Neuropathol."},{"key":"679_CR15","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol. 22, iv1\u2013iv96 (2020).","journal-title":"Neuro Oncol."},{"key":"679_CR16","doi-asserted-by":"publisher","first-page":"9852","DOI":"10.1158\/0008-5472.CAN-06-1796","volume":"66","author":"RB Jenkins","year":"2006","unstructured":"Jenkins, R. B. et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852\u20139861 (2006).","journal-title":"Cancer Res."},{"key":"679_CR17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807\u20131812 (2008).","journal-title":"Science"},{"key":"679_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773 (2009).","journal-title":"N. Engl. J. Med."},{"key":"679_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00401-013-1106-9","volume":"125","author":"C Horbinski","year":"2013","unstructured":"Horbinski, C. What do we know about IDH1\/2 mutations so far, and how do we use it? Acta Neuropathol. 125, 621\u2013636 (2013).","journal-title":"Acta Neuropathol."},{"key":"679_CR20","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat, D. J. et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N. Engl. J. Med. 372, 2481\u20132498 (2015). A seminal paper summarizing The Cancer Genome Atlas data on WHO grade 2\u20133 adult-type diffuse gliomas, which provided the basis for classifiying those tumours by IDH mutation status and codeletion of chromosomes 1p and 19q.","journal-title":"N. Engl. J. Med."},{"key":"679_CR21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","volume":"21","author":"R Appay","year":"2019","unstructured":"Appay, R. et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 21, 1519\u20131528 (2019).","journal-title":"Neuro Oncol."},{"key":"679_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00381-010-1264-1","volume":"27","author":"IF Pollack","year":"2011","unstructured":"Pollack, I. F. et al. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children\u2019s Oncology Group. Childs Nerv. Syst. 27, 87\u201394 (2011).","journal-title":"Childs Nerv. Syst."},{"key":"679_CR23","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.1073\/pnas.1300252110","volume":"110","author":"LA Ramkissoon","year":"2013","unstructured":"Ramkissoon, L. A. et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc. Natl Acad. Sci. USA 110, 8188\u20138193 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"679_CR24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/WNL.0b013e3181e1cf3a","volume":"74","author":"M Labussiere","year":"2010","unstructured":"Labussiere, M. et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 74, 1886\u20131890 (2010).","journal-title":"Neurology"},{"key":"679_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/path.2995","volume":"226","author":"S Yip","year":"2012","unstructured":"Yip, S. et al. Concurrent CIC mutations, IDH mutations, and 1p\/19q loss distinguish oligodendrogliomas from other cancers. J. Pathol. 226, 7\u201316 (2012).","journal-title":"J. Pathol."},{"key":"679_CR26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1750-3639.2010.00453.x","volume":"21","author":"C Horbinski","year":"2011","unstructured":"Horbinski, C. et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol. 21, 564\u2013574 (2011).","journal-title":"Brain Pathol."},{"key":"679_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-013-1095-8","volume":"125","author":"AM Fontebasso","year":"2013","unstructured":"Fontebasso, A. M. et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol. 125, 659\u2013669 (2013).","journal-title":"Acta Neuropathol."},{"key":"679_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","volume":"124","author":"DA Khuong-Quang","year":"2012","unstructured":"Khuong-Quang, D. A. et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 124, 439\u2013447 (2012).","journal-title":"Acta Neuropathol."},{"key":"679_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226\u2013231 (2012).","journal-title":"Nature"},{"key":"679_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm, D. et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425\u2013437 (2012).","journal-title":"Cancer Cell"},{"key":"679_CR31","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow, J. E. et al. Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N. Engl. J. Med. 372, 2499\u20132508 (2015). Along with ref. 20, this paper provides the molecular framework for classifying diffusely infiltrative gliomas in adults.","journal-title":"N. Engl. J. Med."},{"key":"679_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","volume":"136","author":"M Shirahata","year":"2018","unstructured":"Shirahata, M. et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 136, 153\u2013166 (2018).","journal-title":"Acta Neuropathol."},{"key":"679_CR33","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/neuonc\/noz119","volume":"21","author":"C Horbinski","year":"2019","unstructured":"Horbinski, C. et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 21, 1498\u20131508 (2019).","journal-title":"Neuro Oncol."},{"key":"679_CR34","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/neuonc\/noab120","volume":"23","author":"PY Wen","year":"2021","unstructured":"Wen, P. Y. & Packer, R. J. The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol. 23, 1215\u20131217 (2021).","journal-title":"Neuro Oncol."},{"key":"679_CR35","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1200\/JCO.19.02983","volume":"38","author":"EH Bell","year":"2020","unstructured":"Bell, E. H. et al. Comprehensive genomic analysis in NRG oncology\/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J. Clin. Oncol. 38, 3407\u20133417 (2020).","journal-title":"J. Clin. Oncol."},{"key":"679_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","volume":"22","author":"MJ van den Bent","year":"2021","unstructured":"van den Bent, M. J. et al. Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 22, 813\u2013823 (2021).","journal-title":"Lancet Oncol."},{"key":"679_CR37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-4283","author":"CMS Tesileanu","year":"2022","unstructured":"Tesileanu, C. M. S. et al. Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post hoc analysis of the EORTC randomized phase 3 CATNON trial. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4283 (2022).","journal-title":"Clin. Cancer Res."},{"key":"679_CR38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005). A clinical trial that established the combination of radiotherapy and temozolomide for high-grade infiltrative gliomas, a regimen that remains standard-of-care to this day.","journal-title":"N. Engl. J. Med."},{"key":"679_CR39","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller, M. et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat. Rev. Clin. Oncol. 18, 170\u2013186 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"679_CR40","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp, R. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318, 2306\u20132316 (2017). A clinical trial that established electromagnetic tumour-treating fields as a therapeutic option in patients with IDH-wildtype glioblastoma.","journal-title":"JAMA"},{"key":"679_CR41","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/S1470-2045(19)30796-X","volume":"21","author":"TS Armstrong","year":"2020","unstructured":"Armstrong, T. S. et al. Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. Lancet Oncol. 21, e97\u2013e103 (2020).","journal-title":"Lancet Oncol."},{"key":"679_CR42","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","volume":"390","author":"MJ van den Bent","year":"2017","unstructured":"van den Bent, M. J. et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet 390, 1645\u20131653 (2017).","journal-title":"Lancet"},{"key":"679_CR43","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344\u2013350 (2013).","journal-title":"J. Clin. Oncol."},{"key":"679_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","volume":"31","author":"G Cairncross","year":"2013","unstructured":"Cairncross, G. et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J. Clin. Oncol. 31, 337\u2013343 (2013).","journal-title":"J. Clin. Oncol."},{"key":"679_CR45","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","volume":"374","author":"JC Buckner","year":"2016","unstructured":"Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344\u20131355 (2016).","journal-title":"N. Engl. J. Med."},{"key":"679_CR46","unstructured":"National Comprehensive Cancer Network. NCCN Guidelines: Central Nervous System Cancers. Version 2.2021 (NCNN, 2021)."},{"key":"679_CR47","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT00887146 (2022)."},{"key":"679_CR48","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall, S. et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37, 569\u2013583.e5 (2020).","journal-title":"Cancer Cell"},{"key":"679_CR49","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","volume":"10","author":"M Clarke","year":"2020","unstructured":"Clarke, M. et al. Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov. 10, 942\u2013963 (2020).","journal-title":"Cancer Discov."},{"key":"679_CR50","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","volume":"7","author":"A Drilon","year":"2017","unstructured":"Drilon, A. et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400\u2013409 (2017).","journal-title":"Cancer Discov."},{"key":"679_CR51","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41416-018-0251-2","volume":"119","author":"DS Ziegler","year":"2018","unstructured":"Ziegler, D. S. et al. Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br. J. Cancer 119, 693\u2013696 (2018).","journal-title":"Br. J. Cancer"},{"key":"679_CR52","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nox141","volume":"20","author":"DTW Jones","year":"2018","unstructured":"Jones, D. T. W. et al. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 20, 160\u2013173 (2018).","journal-title":"Neuro Oncol."},{"key":"679_CR53","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro, J. et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 20, 1011\u20131022 (2019).","journal-title":"Lancet Oncol."},{"key":"679_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00401-016-1539-z","volume":"131","author":"I Qaddoumi","year":"2016","unstructured":"Qaddoumi, I. et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 131, 833\u2013845 (2016).","journal-title":"Acta Neuropathol."},{"key":"679_CR55","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT02684058 (2022)."},{"key":"679_CR56","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT04201457 (2022)."},{"key":"679_CR57","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT02124772 (2021)."},{"key":"679_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT01089101 (2022)."},{"key":"679_CR59","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT05180825 (2022)."},{"key":"679_CR60","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT02285439 (2022)."},{"key":"679_CR61","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT03155620 (2022)."},{"key":"679_CR62","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT01748149 (2022)."},{"key":"679_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT05222165 (2022)."},{"key":"679_CR64","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997\u20131003 (2005).","journal-title":"N. Engl. J. Med."},{"key":"679_CR65","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2020.11.012","volume":"183","author":"CCL Chen","year":"2020","unstructured":"Chen, C. C. L. et al. Histone H3.3G34-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis. Cell 183, 1617\u20131633.e22 (2020).","journal-title":"Cell"},{"key":"679_CR66","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/neuonc\/now038","volume":"18","author":"RI Jakacki","year":"2016","unstructured":"Jakacki, R. I. et al. Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children\u2019s Oncology Group ACNS0423 study. Neuro Oncol. 18, 1442\u20131450 (2016).","journal-title":"Neuro Oncol."},{"key":"679_CR67","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/neuonc\/noq191","volume":"13","author":"KJ Cohen","year":"2011","unstructured":"Cohen, K. J. et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children\u2019s Oncology Group. Neuro Oncol. 13, 317\u2013323 (2011).","journal-title":"Neuro Oncol."},{"key":"679_CR68","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000521253","volume":"89","author":"BM Man\u00e7ano","year":"2022","unstructured":"Man\u00e7ano, B. M. et al. A unique case report of infant-type hemispheric glioma (gliosarcoma subtype) with TPR-NTRK1 fusion treated with larotrectinib. Pathobiology 89, 178\u2013185 (2022).","journal-title":"Pathobiology"},{"key":"679_CR69","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","volume":"136","author":"A Reinhardt","year":"2018","unstructured":"Reinhardt, A. et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations. Acta Neuropathol. 136, 273\u2013291 (2018).","journal-title":"Acta Neuropathol."},{"key":"679_CR70","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis, M. A. et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol. 16, 1408\u20131416 (2014).","journal-title":"Neuro Oncol."},{"key":"679_CR71","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT03871257 (2022)."},{"key":"679_CR72","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","volume":"30","author":"E Bouffet","year":"2012","unstructured":"Bouffet, E. et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J. Clin. Oncol. 30, 1358\u20131363 (2012).","journal-title":"J. Clin. Oncol."},{"key":"679_CR73","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","volume":"30","author":"JL Ater","year":"2012","unstructured":"Ater, J. L. et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 30, 2641\u20132647 (2012).","journal-title":"J. Clin. Oncol."},{"key":"679_CR74","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397\u2013405 (2011).","journal-title":"Acta Neuropathol."},{"key":"679_CR75","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","volume":"36","author":"T Kaley","year":"2018","unstructured":"Kaley, T. et al. BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J. Clin. Oncol. 36, 3477\u20133484 (2018).","journal-title":"J. Clin. Oncol."},{"key":"679_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen, P. Y. et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 23, 53\u201364 (2022).","journal-title":"Lancet Oncol."},{"key":"679_CR77","first-page":"750","volume":"19","author":"RJ Packer","year":"2017","unstructured":"Packer, R. J. et al. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 19, 750\u2013761 (2017).","journal-title":"Neuro Oncol."},{"key":"679_CR78","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00401-019-02090-0","volume":"139","author":"JE Neumann","year":"2020","unstructured":"Neumann, J. E. et al. Molecular characterization of histopathological ependymoma variants. Acta Neuropathol. 139, 305\u2013318 (2020).","journal-title":"Acta Neuropathol."},{"key":"679_CR79","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","volume":"27","author":"KW Pajtler","year":"2015","unstructured":"Pajtler, K. W. et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27, 728\u2013743 (2015).","journal-title":"Cancer Cell"},{"key":"679_CR80","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/2159-8290.CD-20-1066","volume":"11","author":"A Arabzade","year":"2021","unstructured":"Arabzade, A. et al. ZFTA-RELA dictates oncogenic transcriptional programs to drive aggressive supratentorial ependymoma. Cancer Discov. 11, 2200\u20132215 (2021).","journal-title":"Cancer Discov."},{"key":"679_CR81","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1200\/JCO.2015.65.7825","volume":"34","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy, V. et al. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis. J. Clin. Oncol. 34, 2468\u20132477 (2016).","journal-title":"J. Clin. Oncol."},{"key":"679_CR82","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00401-019-02056-2","volume":"138","author":"DR Ghasemi","year":"2019","unstructured":"Ghasemi, D. R. et al. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol. 138, 1075\u20131089 (2019).","journal-title":"Acta Neuropathol."},{"key":"679_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11060-015-1955-2","volume":"126","author":"P Bandopadhayay","year":"2016","unstructured":"Bandopadhayay, P. et al. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J. Neuro Oncol. 126, 165\u2013174 (2016).","journal-title":"J. Neuro Oncol."},{"key":"679_CR84","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1016\/j.wneu.2019.12.128","volume":"136","author":"A Abdallah","year":"2020","unstructured":"Abdallah, A. et al. Long-term surgical resection outcomes of pediatric myxopapillary ependymoma: experience of two centers and brief literature review. World Neurosurg. 136, e245\u2013e261 (2020).","journal-title":"World Neurosurg."},{"key":"679_CR85","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","volume":"133","author":"KW Pajtler","year":"2017","unstructured":"Pajtler, K. W. et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol. 133, 5\u201312 (2017).","journal-title":"Acta Neuropathol."},{"key":"679_CR86","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00401-017-1752-4","volume":"134","author":"P Panwalkar","year":"2017","unstructured":"Panwalkar, P. et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. Acta Neuropathol. 134, 705\u2013714 (2017).","journal-title":"Acta Neuropathol."},{"key":"679_CR87","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/neuonc\/noab230","volume":"24","author":"M Massimino","year":"2021","unstructured":"Massimino, M. et al. Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol. Neuro Oncol. 24, 467\u2013479 (2021).","journal-title":"Neuro Oncol."},{"key":"679_CR88","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00401-021-02300-8","volume":"141","author":"C Thomas","year":"2021","unstructured":"Thomas, C. et al. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma. Acta Neuropathol. 141, 959\u2013970 (2021).","journal-title":"Acta Neuropathol."},{"key":"679_CR89","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1093\/neuonc\/noab034","volume":"23","author":"LV Baroni","year":"2021","unstructured":"Baroni, L. V. et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro Oncol. 23, 1360\u20131370 (2021).","journal-title":"Neuro Oncol."},{"key":"679_CR90","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/neuonc\/not121","volume":"15","author":"SM Macdonald","year":"2013","unstructured":"Macdonald, S. M. et al. Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro Oncol. 15, 1552\u20131559 (2013).","journal-title":"Neuro Oncol."},{"key":"679_CR91","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41568-021-00433-2","volume":"22","author":"AH Saleh","year":"2022","unstructured":"Saleh, A. H. et al. The biology of ependymomas and emerging novel therapies. Nat. Rev. Cancer 22, 208\u2013222 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"679_CR92","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01260-w","author":"R Ruda","year":"2022","unstructured":"Ruda, R., Bruno, F., Pellerino, A. & Soffietti, R. Ependymoma: evaluation and management updates. Curr. Oncol. Rep. https:\/\/doi.org\/10.1007\/s11912-022-01260-w (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"679_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac043","author":"E Le Rhun","year":"2022","unstructured":"Le Rhun, E. et al. Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noac043 (2022).","journal-title":"Neuro Oncol."},{"key":"679_CR94","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3171\/2014.1.PEDS13532","volume":"13","author":"S Kukreja","year":"2014","unstructured":"Kukreja, S., Ambekar, S., Sin, A. H. & Nanda, A. Cumulative survival analysis of patients with spinal myxopapillary ependymomas in the first 2 decades of life. J. Neurosurg. Pediatr. 13, 400\u2013407 (2014).","journal-title":"J. Neurosurg. Pediatr."},{"key":"679_CR95","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1200\/JCO.2012.48.5052","volume":"31","author":"N Zhukova","year":"2013","unstructured":"Zhukova, N. et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J. Clin. Oncol. 31, 2927\u20132935 (2013).","journal-title":"J. Clin. Oncol."},{"key":"679_CR96","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.20.01372","volume":"39","author":"A Gajjar","year":"2021","unstructured":"Gajjar, A. et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). J. Clin. Oncol. 39, 822\u2013835 (2021).","journal-title":"J. Clin. Oncol."},{"key":"679_CR97","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s00401-021-02358-4","volume":"142","author":"H Coltin","year":"2021","unstructured":"Coltin, H. et al. Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathol. 142, 859\u2013871 (2021).","journal-title":"Acta Neuropathol."},{"key":"679_CR98","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(18)30532-1","volume":"19","author":"T Goschzik","year":"2018","unstructured":"Goschzik, T. et al. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT\/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncol. 19, 1602\u20131616 (2018).","journal-title":"Lancet Oncol."},{"key":"679_CR99","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","volume":"138","author":"T Sharma","year":"2019","unstructured":"Sharma, T. et al. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of group 3 and group 4 subtypes. Acta Neuropathol. 138, 309\u2013326 (2019).","journal-title":"Acta Neuropathol."},{"key":"679_CR100","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/bpa.12413","volume":"27","author":"PD Johann","year":"2017","unstructured":"Johann, P. D. et al. Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathol. 27, 411\u2013418 (2017).","journal-title":"Brain Pathol."},{"key":"679_CR101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/10935266211018554","volume":"25","author":"JA Cotter","year":"2022","unstructured":"Cotter, J. A. & Judkins, A. R. Evaluation and diagnosis of central nervous system embryonal tumors (non-medulloblastoma). Pediatr. Dev. Pathol. 25, 34\u201345 (2022).","journal-title":"Pediatr. Dev. Pathol."},{"key":"679_CR102","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","volume":"164","author":"D Sturm","year":"2016","unstructured":"Sturm, D. et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164, 1060\u20131072 (2016).","journal-title":"Cell"},{"key":"679_CR103","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bpa.12747","volume":"30","author":"SP Ferris","year":"2020","unstructured":"Ferris, S. P. et al. High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication\u2013 a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathol. 30, 46\u201362 (2020).","journal-title":"Brain Pathol."},{"key":"679_CR104","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003088","volume":"3","author":"M Kool","year":"2008","unstructured":"Kool, M. et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 3, e3088 (2008).","journal-title":"PLoS ONE"},{"key":"679_CR105","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.19.03057","volume":"38","author":"M Mynarek","year":"2020","unstructured":"Mynarek, M. et al. Nonmetastatic medulloblastoma of early childhood: results from the prospective clinical trial HIT-2000 and an extended validation cohort. J. Clin. Oncol. 38, 2028\u20132040 (2020).","journal-title":"J. Clin. Oncol."},{"key":"679_CR106","doi-asserted-by":"publisher","first-page":"38827","DOI":"10.18632\/oncotarget.5149","volume":"6","author":"SC Clifford","year":"2015","unstructured":"Clifford, S. C. et al. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget 6, 38827\u201338839 (2015).","journal-title":"Oncotarget"},{"key":"679_CR107","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT02724579 (2022)."},{"key":"679_CR108","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","volume":"131","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy, V. et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 131, 821\u2013831 (2016).","journal-title":"Acta Neuropathol."},{"key":"679_CR109","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.20.02730","volume":"39","author":"JM Michalski","year":"2021","unstructured":"Michalski, J. M. et al. Children\u2019s Oncology Group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 39, 2685\u20132697 (2021).","journal-title":"J. Clin. Oncol."},{"key":"679_CR110","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1200\/JCO.2006.06.4980","volume":"24","author":"RJ Packer","year":"2006","unstructured":"Packer, R. J. et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J. Clin. Oncol. 24, 4202\u20134208 (2006).","journal-title":"J. Clin. Oncol."},{"key":"679_CR111","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1001\/jamaoncol.2021.2224","volume":"7","author":"SES Leary","year":"2021","unstructured":"Leary, S. E. S. et al. Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the Children\u2019s Oncology Group. JAMA Oncol. 7, 1313\u20131321 (2021).","journal-title":"JAMA Oncol."},{"key":"679_CR112","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa042176","volume":"352","author":"S Rutkowski","year":"2005","unstructured":"Rutkowski, S. et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N. Engl. J. Med. 352, 978\u2013986 (2005).","journal-title":"N. Engl. J. Med."},{"key":"679_CR113","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1200\/JCO.19.00845","volume":"38","author":"L Lafay-Cousin","year":"2020","unstructured":"Lafay-Cousin, L. et al. Phase II study of nonmetastatic desmoplastic medulloblastoma in children younger than 4 years of age: a report of the Children\u2019s Oncology Group (ACNS1221). J. Clin. Oncol. 38, 223\u2013231 (2020).","journal-title":"J. Clin. Oncol."},{"key":"679_CR114","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/cancers14030837","volume":"14","author":"L Lafay-Cousin","year":"2022","unstructured":"Lafay-Cousin, L. & Dufour, C. High-dose chemotherapy in children with newly diagnosed medulloblastoma. Cancers 14, 837 (2022).","journal-title":"Cancers"},{"key":"679_CR115","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/pbc.26042","volume":"63","author":"L Lafay-Cousin","year":"2016","unstructured":"Lafay-Cousin, L. et al. Clinical, pathological, and molecular characterization of infant medulloblastomas treated with sequential high-dose chemotherapy. Pediatr. Blood Cancer 63, 1527\u20131534 (2016).","journal-title":"Pediatr. Blood Cancer"},{"key":"679_CR116","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(18)30204-3","volume":"19","author":"GW Robinson","year":"2018","unstructured":"Robinson, G. W. et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol. 19, 768\u2013784 (2018).","journal-title":"Lancet Oncol."},{"key":"679_CR117","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41568-019-0223-8","volume":"20","author":"V Hovestadt","year":"2020","unstructured":"Hovestadt, V. et al. Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nat. Rev. Cancer 20, 42\u201356 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"679_CR118","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.21.00784","volume":"39","author":"SLN Maas","year":"2021","unstructured":"Maas, S. L. N. et al. Integrated molecular-morphologic meningioma classification: a multicenter retrospective analysis, retrospectively and prospectively validated. J. Clin. Oncol. 39, 3839\u20133852 (2021).","journal-title":"J. Clin. Oncol."},{"key":"679_CR119","doi-asserted-by":"publisher","first-page":"djv377","DOI":"10.1093\/jnci\/djv377","volume":"108","author":"F Sahm","year":"2016","unstructured":"Sahm, F. et al. TERT promoter mutations and risk of recurrence in meningioma. J. Natl Cancer Inst. 108, djv377 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"679_CR120","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1093\/neuonc\/noab213","volume":"24","author":"J Driver","year":"2021","unstructured":"Driver, J. et al. A molecularly integrated grade for meningioma. Neuro Oncol. 24, 796\u2013808 (2021).","journal-title":"Neuro Oncol."},{"key":"679_CR121","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri, F. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"679_CR122","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/neuonc\/noz061","volume":"21","author":"F Nassiri","year":"2019","unstructured":"Nassiri, F. et al. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. 21, 901\u2013910 (2019).","journal-title":"Neuro Oncol."},{"key":"679_CR123","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","volume":"18","author":"F Sahm","year":"2017","unstructured":"Sahm, F. et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol. 18, 682\u2013694 (2017).","journal-title":"Lancet Oncol."},{"key":"679_CR124","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-022-01061-8","volume":"54","author":"A Choudhury","year":"2022","unstructured":"Choudhury, A. et al. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat. Genet. 54, 649\u2013659 (2022).","journal-title":"Nat. Genet."},{"key":"679_CR125","doi-asserted-by":"publisher","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","volume":"21","author":"PK Brastianos","year":"2019","unstructured":"Brastianos, P. K. et al. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 21, i18\u2013i31 (2019).","journal-title":"Neuro Oncol."},{"key":"679_CR126","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.11.028","volume":"106","author":"CL Rogers","year":"2020","unstructured":"Rogers, C. L. et al. High-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539. Int. J. Radiat. Oncol. Biol. Phys. 106, 790\u2013799 (2020).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"679_CR127","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/neuonc\/nox166","volume":"20","author":"R Ruda","year":"2018","unstructured":"Ruda, R. et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol. 20, 445\u2013456 (2018).","journal-title":"Neuro Oncol."},{"key":"679_CR128","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.18.01765","volume":"37","author":"TE Merchant","year":"2019","unstructured":"Merchant, T. E. et al. Conformal radiation therapy for pediatric ependymoma, chemotherapy for incompletely resected ependymoma, and observation for completely resected, supratentorial ependymoma. J. Clin. Oncol. 37, 974\u2013983 (2019).","journal-title":"J. Clin. Oncol."},{"key":"679_CR129","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature26000","volume":"555","author":"D Capper","year":"2018","unstructured":"Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469\u2013474 (2018). A landmark study that demonstrated the ability of whole-genomic DNA methylation profilng to classify CNS tumours, including those that are difficult to classify by traditional microscopy and next-generation sequencing.","journal-title":"Nature"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00679-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00679-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00679-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T06:08:57Z","timestamp":1668406137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00679-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":129,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["679"],"URL":"https:\/\/doi.org\/10.1038\/s41582-022-00679-w","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"24 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}